Evidence map›Paper›PMID 22961473›Full record

ArticleNeuroscience bulletin2012

Schizandrin prevents dexamethasone-induced cognitive deficits.

Xiao Xu, Xing Zhou, Xiao-Wen Zhou, Zheng Zhang, Min-Jing Liao, Qi Gao, Huan-Min Luo

Open access · bronzeAbstract read
In one paragraph

Article in Neuroscience bulletin, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. A comprehensive review on Schisandrin and its pharmacological features.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  5. Article
  6. Schizandrol A protects against AβNaunyn-Schmiedeberg's archives of pharmacology · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xiao XuDepartment of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, China.
Xing Zhou
Xiao-Wen Zhou
Zheng Zhang
Min-Jing Liao
Qi Gao
Huan-Min Luo
Jinan University · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo model glucocorticoid-induced cognitive impairment and evaluate the neuroprotection by schizandrin (Sch) against dexamethasone (Dex)-induced neurotoxicity in vivo and in vitro.

methodsCerebral cortical cells from neonatal Sprague-Dawley rats (within 24 hours after birth) were cultured for 9 days, and then treated with Dex (10(-4), 10(-5), 10(-6) or 10(-7) mol/L) for 24 h or pretreated with 10(-4) mol/L Dex for 24 h followed by 10, 20, 40, or 80 μmol/L Sch for 48 h. Cell viability was assessed using the MTT assay. Immunofluorescence and real-time PCR for MAP2 were performed to confirm the effects of Dex on neurite outgrowth. In vivo, kunming mice were randomly divided into six groups: control [(intragastric (i.g.) vehicle for 42 days]; Dex group I (5 mg/kg · d(-1) Dex i.g. treatment for 28 days followed by i.g. vehicle for 14 days); Dex group II (Dex i.g. for 42 days); Dex + Sch (Dex i.g. for 28 days followed by 5, 15, or 45 mg/kg · d(-1) Sch i.g. for 14 days). Learning and memory were assessed by Morris water maze test. Histological examination was used to assess pathology and apoptosis in neurons.

resultsCompared to the Dex groups, Sch increased cell viability in a dose-dependent manner, improved performance in the Morris water maze and ameliorated the morphological changes.

conclusionSch has neuroprotective effects against insults induced by glucocorticoid.

Indexed as

SchisandraAnimalsAnimals, NewbornCells, CulturedCell SurvivalCerebral CortexCognition DisordersCyclooctanesDexamethasoneDose-Response Relationship, DrugLignansMaleMiceNeuroprotective AgentsPolycyclic CompoundsRandom AllocationCyclooctanesDexamethasoneLignansNeuroprotective AgentsPolycyclic Compoundsschizandrin

Identifiers

PMID22961473
PMCPMC5561910
OpenAlexW1976293247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.